206 related articles for article (PubMed ID: 37395601)
21. A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma.
Lolli C; Altavilla A; Conteduca V; Farolfi A; Casadei C; Schepisi G; Banna GL; De Giorgi U
Crit Rev Oncol Hematol; 2020 Sep; 153():103036. PubMed ID: 32650216
[TBL] [Abstract][Full Text] [Related]
22. Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study.
Kankuri-Tammilehto M; Perasto L; Pyrhonen S; Salminen E
Anticancer Res; 2023 Jun; 43(6):2645-2657. PubMed ID: 37247917
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors.
Delcuratolo MD; Tucci M; Turco F; Di Stefano RF; Ungaro A; Audisio M; Samuelly A; Brusa F; Audisio A; Di Maio M; Scagliotti GV; Buttigliero C
Crit Rev Oncol Hematol; 2023 Jan; 181():103881. PubMed ID: 36427772
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of IL-2-induced cytotoxicity by interferon-alpha in renal cell carcinoma.
Naoe M; Ogawa Y; Hasebe Y; Morita J; Shichijo T; Igarashi A; Fuji K; Iwamoto S; Suzuki T; Terao S
Oncol Res; 2011; 19(10-11):479-86. PubMed ID: 22715591
[TBL] [Abstract][Full Text] [Related]
28. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
29. Safety of available treatment options for renal cell carcinoma.
Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
[TBL] [Abstract][Full Text] [Related]
30. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
31. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Sandmeier N; Rothschild SI; Rothermundt C; Cathomas R; Schardt J; Berthold D; von Burg P; Müller B; Beyer J; Vogt DR; Stenner F
Clin Genitourin Cancer; 2018 Aug; 16(4):e711-e718. PubMed ID: 29503245
[TBL] [Abstract][Full Text] [Related]
32. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
33. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
34. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Gao X; McDermott DF
Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
[TBL] [Abstract][Full Text] [Related]
36. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
[TBL] [Abstract][Full Text] [Related]
37. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Hara T; Miyake H; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):363-369. PubMed ID: 28169111
[TBL] [Abstract][Full Text] [Related]
38. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Ravi P; Mantia C; Su C; Sorenson K; Elhag D; Rathi N; Bakouny Z; Agarwal N; Zakharia Y; Costello BA; McKay RR; Narayan V; Alva A; McGregor BA; Gao X; McDermott DF; Choueiri TK
JAMA Oncol; 2020 Oct; 6(10):1606-1610. PubMed ID: 32469396
[TBL] [Abstract][Full Text] [Related]
40. How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?
Melichar B
Oncology; 2009; 77(2):82-91. PubMed ID: 19602908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
